ArticleJDS communications2026
Administering the maternal bovine appeasing substance improves fertility in lactating dairy cows.
Article in JDS communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of the Use of Bovine Appeasing Substance on Immunological, Metabolic, and Oxidative Parameters of Postpartum Dairy Cows: Modulation of the Stress Axis.Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This experiment evaluated the effects of administering the maternal bovine appeasing substance (mBAS) at the time of artificial insemination (AI) on pregnancy per AI (P/AI) of Holstein cows under commercial dairy conditions. A total of 375 lactating Holstein dairy cows (178 primiparous and 197 multiparous cows) from 2 commercial dairy farms were enrolled. All cows were assigned to an ovulation synchronization + AI protocol when they reached 65 DIM. The protocol included 2 mg of estradiol benzoate + intravaginal progesterone-releasing device (DIB) on d -10, followed by 25 mg of dinoprost tromethamine on d -3, followed by 25 mg of dinoprost tromethamine + 1 mg of estradiol cypionate + 400 IU of equine chorionic gonadotropin + DIB removal and tail paint on d -2. On d 0 (24 h after tail paint application), cows with paint removed were classified as in estrus and inseminated. Cows with intact tail paint were considered not to be in estrus, administered 100 µg of GnRH, and inseminated 8 h later. At the time of AI, cows within farm and parity were randomly assigned to receive mBAS (Ferappease, FERA Diagnostics and Biologicals, College Station, TX; n = 197) or no treatment (CON, n = 178). The mBAS (10 mL) was applied topically to the nuchal skin area (5 mL) and above the muzzle (5 mL). Pregnancy status to AI was verified by detecting a viable embryo with transrectal ultrasonography 32 d after AI. Cows assigned to mBAS or CON had similar DIM at the time of AI, milk yield, and incidence of estrus during the synchronization protocol. Administering mBAS increased P/AI by 12.5 percentage points compared with CON cows (60.2% vs. 47.7%). Based on treatment differences in P/AI and an economic value of $200/pregnancy, mBAS administration yielded a return-on-investment of 833%. This calculation assumed mBAS cost of $3.00/cow, a herd of 1,000 cows in which mBAS yielded 125 more pregnancies, resulting in an economic benefit of $25,000 ($25,000/$3,000 = 8.33). The results of this experiment are novel and provide evidence that mBAS is effective in enhancing the reproductive performance of lactating dairy cows when applied during critical stress-sensitive periods such as AI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.